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Abstract
Background: Pneumocystis pneumonia (PCP) is a major cause of hospitalization and mortality in HIV-infected
African children. Microbiologic diagnosis relies predominantly on silver or immunofluorescent staining of a lower
respiratory tract (LRT) specimens which are difficult to obtain in children. Diagnosis on upper respiratory tract (URT)
specimens using PCR has been reported useful in adults, but data in children are limited. The main objectives of
the study was (1) to compare the diagnostic yield of PCR with immunofluorescence (IF) and (2) to investigate the
usefulness of upper compared to lower respiratory tract samples for diagnosing PCP in children.
Methods: Children hospitalised at an academic hospital with suspected PCP were prospectively enrolled. An upper
respiratory sample (nasopharyngeal aspirate, NPA) and a lower respiratory sample (induced sputum, IS or
bronchoalveolar lavage, BAL) were submitted for real-time PCR and direct IF for the detection of Pneumocystis
jirovecii. A control group of children with viral lower respiratory tract infections were investigated with PCR for PCP.
Results: 202 children (median age 3.3 [inter-quartile range, IQR 2.2 - 4.6] months) were enrolled. The overall
detection rate by PCR was higher than by IF [180/349 (52%) vs. 26/349 (7%) respectively; p < 0.0001]. PCR detected
more infections compared to IF in lower respiratory tract samples [93/166 (56%) vs. 22/166 (13%); p < 0.0001] and
in NPAs [87/183 (48%) vs. 4/183 (2%); p < 0.0001]. Detection rates by PCR on upper (87/183; 48%) compared with
lower respiratory tract samples (93/166; 56%) were similar (OR, 0.71; 95% CI, 0.46 - 1.11). Only 2/30 (6.6%) controls
were PCR positive.
Conclusion: Real-time PCR is more sensitive than IF for the detection of P. jirovecii in children with PCP. NPA
samples may be used for diagnostic purposes when PCR is utilised. Wider implementation of PCR on NPA samples
is warranted for diagnosing PCP in children.
Background
Pneumocystis pneumonia (PCP), caused by Pneumocystis
jirovecii, is an important opportunistic infection in HIV-
infected children [1,2]. The incidence of PCP in devel-
oped countries has declined since the introduction of
highly active anti-retroviral therapy and use of chemo-
prophylaxis. However, PCP remains a major cause of
hospitalization and mortality in HIV-infected children in
low or middle income countries, [1,3-5] with reported
incidence rates of 10 - 49%, [1,3,6] and in-hospital case-
fatality rates of 20 - 63% [1,3,4,6]. Apart from HIV
infection, there are other factors that predispose chil-
dren to developing PCP including malnutrition, other
immune deficiencies or HIV exposure. Untreated, the
case fatality rate in children with PCP approximates
100% [1,3,4,6]. However, diagnosis can be difficult as
clinical and radiological findings are non-specific.
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important for timely use of appropriate medication.
Detection of P. jirovecii is hampered by the lack of a
sustainable in-vitro culture method [7]. Standard labora-
tory diagnostic methods are microscopic examination of
a lower respiratory tract sample with Gomori Grocott’s
methenamine silver nitrate stain or the more sensitive
immunofluorescence assay (IF) [8] on bronchoalveolar
lavage (BAL) or induced sputum (IS) specimens. Using
microscopy, the yield from IS has been reported to be
s i m i l a rc o m p a r e dt ot h a tf r o mB A L[ 9 ] .H o w e v e r ,s p u -
tum induction in children is not widely performed,
requires staff trained to do the procedure and may
result in clinical deterioration or nosocomial transmis-
sion of respiratory pathogens. Diagnosis using a non-
invasive sample such as a nasopharyngeal aspirate
(NPA) is, therefore, desirable.
The clinical sensitivity from a NPA has been reported
to be low and variable when microscopy is utilised
[4,5,10]. The development of polymerase chain reaction
( P C R )t e c h n i q u e sh a sp r o v i d e dam o r er e l i a b l ed i a g n o s -
tic method. In adult studies, PCR is as specific as and
more sensitive than microscopy for diagnosis when per-
formed on respiratory specimens, including oral washes
[7,11-21]. In a study of oropharyngeal washes from
HIV-infected adult patients, P. jirovecii DNA-amplifica-
tion had a sensitivity of 44% using a nested PCR proto-
col compared to trans-bronchial biopsy, [16] increasing
to 90% when touch-down real-time PCR was utilised
[7,11]. Real-time PCR also allows for quantification of
the organism load and with application of cutoff values,
could improve the specificity by distinguishing between
colonization and infection [13].
The aims of this study were (1) to compare a real-time
quantitative PCR assay with IF for the diagnosis of PCP
in children and (2) to evaluate the reliability of PCR for
the diagnosis of PCP in upper compared to lower
respiratory tract secretions.
Methods
Participants
Consecutive children (<14 years old) with suspected
PCP, hospitalized at Red Cross War Memorial Chil-
dren’s Hospital, Cape Town, South Africa, were enrolled
from November 2006 to August 2008. Clinical criteria
for suspected PCP were an acute onset of a respiratory
illness, presence of age-specific tachypnoea and hypoxia,
bilateral lung disease (not associated with wheezing) and
a risk factor for PCP (HIV-infected, HIV-exposed, mal-
nourished, receiving immunosuppressive therapy or
immunodeficiency disease other than HIV). Patients
were excluded if they had received treatment for PCP in
the preceding 2 weeks or were on PCP treatment for
more than 48 hours. A child was defined as HIV-
infected if they had a positive HIV PCR (Amplicor HIV-
1 DNA test version 1.5, Roche Diagnostics GmbH, Man-
nheim, Germany) if younger than 18 months or a posi-
tive HIV ELISA (Architect HIV Ag/Ab Combo ELISA,
Abbott Laboratories, Abbott Park, IL) in older children.
HIV exposure in infants less than 18 months was
defined as being HIV sero-positive with a negative HIV
PCR. Children were treated according to a standard pro-
tocol for severe pneumonia that included intravenous
co-trimoxazole and oral corticosteroids, as well as
broad-spectrum antibiotics. Other antimicrobial therapy
was added at the discretion of the attending clinician.
Written informed consent w a so b t a i n e df r o map a r e n t
or legal guardian. The study was approved by the
Research Ethics Committee of the Faculty of Health
Sciences at the University of Cape Town.
Sample collection
An upper respiratory tract sample (NPA) and a lower
respiratory tract sample (IS in non-intubated patients or
BAL in intubated patients) were obtained using standar-
dised methods at the time of admission [11,22]. NPA
specimens were obtained first, followed by LRT speci-
mens. After routine laboratory investigations had been
performed, an aliquot of sample was frozen at -70°C for
analysis by PCR.
Control group
Respiratory samples (NPA or BAL) from 30 children
sequentially hospitalized with a confirmed viral LRT
infection, who were randomly selected and who
improved clinically without specific treatment for PCP,
were investigated with PCR for PCP, as a control group.
Laboratory investigations
Direct immunofluorescence (IF) (Detect IF PC, Axis-
Shield Diagnostics, Cambridgeshire, United Kingdom),
to detect cystic forms of P. jirovecii using a monoclonal
antibody immunofluorescent stain, was performed
according to the manufacturer’s instructions. Accord-
ingly, results were reported as positive if more than 5
cysts were observed. In addition, Grocott’s methenamine
silver nitrate stain was performed on BAL specimens, as
per clinician’s request, if sufficient sample volume was
available.
DNA was isolated using the Nuclisens EasyMAG plat-
form (bioMérieux, Boxtel, Netherlands). P. jirovecii
DNA was detected using a quantitative, touch-down,
real-time PCR assay, targeting the major surface glyco-
protein (MSG) gene as described by Larsen et al [13].
Commercially synthesized primers, amplifying a 250-bp
segment of the multicopy MSG gene family, were uti-
lized in a PCR reaction containing fluorescence reso-
nance energy transfer (FRET) probes for detection of
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was cloned into the pCR 2.1 vector. Four external stan-
dards of the cloned target template, corresponding to
10
6,1 0
5,1 0
4 and 10
3 copies per microlitre, were used in
each PCR run to generate an external standard curve,
required for quantification. The reactions were per-
formed on the LightCycler platform (Roche Diagnostics
GmbH, Mannheim, Germany) and results were calcu-
lated using the LightCycler software and expressed in
copies/mL. A P. jirovecii positive and a negative control
were included in each PCR run. Laboratory testing was
conducted in an ISO-accredited molecular laboratory of
the National Health Laboratory Service (NHLS) at
Groote Schuur Hospital, Cape Town. The laboratory is
designed with separate areas for DNA extraction, PCR
preparation, DNA addition, and amplification, in order
to reduce the chance of cross contamination. Use of a
real-time PCR platform minimised the chance of con-
tamination during the detection step. The investigators
who performed the PCR testing were blinded to the IF
or silver stain results.
Data Analysis
Statistical analysis was performed using statistical soft-
ware Stata (version 10.0, StataCorp, Houston, USA).
Continuous data was tested for normality using the Sha-
piro-Wilk test. Detection rates of PCR were compared
by Pearson’s chi-squared test and quantification results
were compared by Wilcoxon rank-sum (Mann-Whitney)
test. Paired analysis of continuous and binary variables
was performed using t test and chi-squared test,
respectively.
Results
Patient characteristics
212 children were enrolled (Table 1); 10 patients were
excluded as there was insufficient respiratory sample left
for PCR, thus 202 children were included in this analy-
sis. Of these, 92 (46%) were male; the median (IQR) age
was 3.3 (2.2 - 4.6) months. HIV status was determined
in 200 (99%) patients, of whom 129 (65%) were HIV-
infected. Of the 71 (35%) HIV-uninfected children, 32
(45%) were HIV-exposed. Twenty-seven (21%) of the
129 HIV-infected children were on co-trimoxazole
prophylaxis at presentation. The median (IQR) CD4 per-
centage of HIV-infected children was 16.9% (10.1 - 27.1)
PCR and IF on patient samples
349 respiratory samples were obtained. One hundred
and forty-seven (73%) children had paired samples con-
sisting of a NPA with either a BAL or IS. Fifty-five chil-
dren produced a single respiratory sample (Table 2).
Real-time PCR performed on 349 respiratory samples
detected P. jirovecii in 180 specimens (52%) (Table 3).
Of the 202 patients, 110 (54.5%) had one or more speci-
mens positive by PCR. The HIV status was determined
in 109 of these 110 patients. 92 (84%) of the 109
patients with a positive PCR result were HIV infected.
This was significantly higher than in the total cohort of
patients where 65% were found to be HIV-infected
(Odds-ratio OR, 7.9; 95% CI 3.9-16.3; p < 0.0001).
Overall, P. jirovecii DNA was detected in 37 of 66
(56%) BAL specimens, 56 of 100 (56%) IS and 87 of 183
(48%) NPA. There was no significant difference between
the detection by PCR on LRT samples compared to
NPA (OR, 0.71; 95% CI, 0.46 - 1.11; Table 3).
In contrast, P. jirovecii was detected by IF in 26 (7%)
of samples, consisting of 13 (50%) BAL, 9 (35%) IS and
4 (15%) NPA samples. All 26 IF-positive samples were
positive on PCR and thus no additional cases were
detected using IF. The overall yield on upper tract sam-
ples was 48% (87/183) by PCR, as compared to the yield
of 2% (4/183) by IF (OR 40.5; 95% CI, 14.4-113.8; p <
0.0001). For lower tract samples, the yield from PCR
was 56% (93/166) compared to 13% (22/166) by IF (OR
8.3; 95% CI, 4.8-14.3; p < 0.0001).
P. jirovecii was also demonstrated on silver stain in 8
of the 25 (32%) BAL samples sent for analysis. All 8
were also PCR positive, and 3 were IF positive. Of the
17 patients with a negative BAL silver stain, 5 (29%)
were PCR-positive and 3 were also IF positive.
Comparison of yield by PCR on paired upper and lower
respiratory tract samples
Of the 147 paired upper and lower respiratory tract
samples, 70 pairs were concordant PCR-positive, 63
pairs were concordant PCR-negative and 14 pairs had
discordant PCR results. Of the discordant pairs, most
Table 1 Baseline characteristics of children admitted to hospital with suspected Pneumocystis jirovecii pneumonia
Characteristic All Patients (n = 202) Patients with positive PCR for PCP (n = 110)
Male 92 (46%) 49 (45%)
Median age, IQR, months 3.3 (2.2-4.6) 3.4 (2.7-3.9)
HIV positive 129/200 (65%) 92/109 (84%)
Median CD4 percentage*, IQR, % 16.9 (10.1-27.1) 13.6 (9.0-18.0)
Cotrimoxazole prophylaxis* 27 (21%) 10 11%)
* In HIV-infected children
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tive on the upper tract sample (Table 4). Overall, the
detection from upper and lower specimens by PCR was
similar with 81 of 147 (55%) lower respiratory tract sam-
ples positive by PCR vs. 73 of 147 (50%) NPA samples
(OR, 1.4; 95% CI, 0.91-2.19). Only 8 (5%) additional
cases were detected by PCR when performed on a lower
respiratory tract sample compared to a NPA specimen
(p = 0.11). Using a positive PCR result on a lower
respiratory tract sample as a gold standard, the sensitiv-
ity, specificity, positive predictive value and negative pre-
dictive value for PCR on a NPA sample was 86%, 95%,
96% and 85% respectively.
Concentrations of P. jirovecii DNA ranged from 3.2 to
9.4 log copies/mL. The median (IQR) organism load
detected in NPA samples was significantly lower than
that detected in lower respiratory tract samples [5.9 (5.4
- 6.7) log copies/ml compared to 6.6 (5.8 - 7.5) log
copies/mL; p = 0.0002).
Control group
Of the 30 children in the control group, 18 (60%) were
male; the median (IQR) age was 6.0 (4.0 - 12.0) months.
HIV status was determined in 21 (70%) patients, of whom
2 (10%) were HIV-infected, 6 (28%) were HIV-exposed
and 13 (62%) were HIV-unexposed. Twenty-eight (93%) of
30 control samples were PCR-negative. The 2 PCR posi-
tive samples (both NPA samples), were from HIV-unex-
posed infants, younger than 6 months old, with DNA
concentrations of 6.1 and 6.7 log copies/mL.
Discussion
This study found that PCR had a much higher sensitiv-
ity than the current standard diagnostic test of IF, with
a more than 5 fold increased detection in upper and
lower samples using PCR. In addition, an URT specimen
was as reliable as a LRT specimen for PCR confirmed
diagnosis. To our knowledge, this is the first study in
children that demonstrates that P. jirovecii can be reli-
ably detected using PCR on an upper respiratory tract
specimen. The increase in diagnostic yield using PCR
occurred in both upper and LRT specimens, but was
especially marked in upper respiratory samples. This is
important as obtaining a LRT specimen using BAL or IS
in children can be difficult whereas obtaining a NPA is
much easier, and carries a lower risk of nosocomial
transmission of infection, thus making the diagnosis of
PCP feasible in many health-care settings, including in
primary care. The detection of organism in an URT
sample may occur due to extension of infection to the
upper airways in severe disease or by organisms that are
propelled to the upper airway during coughing [16].
Using current methods of detection with staining, PCP
may therefore be substantially under-diagnosed in chil-
dren. This is supported by the low rates of laboratory
confirmation of approximately 20% reported in clinical
studies of children with suspected PCP [1,3]. When IF
on LRT samples was used as the reference standard, the
sensitivity of the PCR assay was 100%.
A further advantage of PCR is the rapid turn-around
time of the test, with results obtainable within hours.
Children with PCP often have a rapidly progressive
course, thus timely diagnosis would allow early initiation
of treatment in those not on treatment, with potential
reduction in mortality. The usual management of sus-
pected PCP is empiric treatment with co-trimoxazole
and corticosteroids in children who are hypoxic. Rapid
confirmation of diagnosis would therefore also be useful
for guiding corticosteroid therapy. This is especially
relevant given the concerns about use of corticosteroids
in other infections such as CMV pneumonitis or TB in
children, without specific antimicrobial therapy for these
Table 2 Sources of the 349 samples from 202 patients
included in the study
Unpaired
Samples
Paired Samples Total
Samples
NPA
+IS
NPA
+BAL
NPA 36 92 55 183
IS 8 92 - 100
BAL 11 - 55 66
Total
Samples
55 184 110 349
URT, upper respiratory tract; LRT, lower respiratory tract; NPA, nasopharyngeal
aspirate; IS, induced sputum; BAL, bronchoalveolar lavage
Table 3 Quantitative PCR and Direct IF performed on 349
respiratory samples collected from 202 patients
TOTAL URT LRT OR (95% CI)
(n = 349) (n = 183) (n = 166)
Positive PCR 180 (52%) 87 (48%) 93 (56%) 0.71 (0.46 - 1.11)
Positive IF 26 (7%) 4 (2%) 22 (13%) 0.15 (0.04 - 0.45)
URT, upper respiratory tract; LRT, lower respiratory tract; OR, Odds-ratio; CI,
confidence interval; PCR, polymerase chain reaction; IF, immunofluorescence
Table 4 Real-time PCR results on paired upper and lower
respiratory tract samples (n = 147)
LRT Sample LRT Sample Total
(IS/BAL)
Positive
(IS/BAL)
Negative
URT Sample (NPA)
Positive
70 (48%) 3 (2%) 73
(50%)
URT Sample (NPA)
Negative
11 (7%) 63 (43%) 74
(50%)
Total 81 66 147
URT, upper respiratory tract; LRT, lower respiratory tract; NPA, nasopharyngeal
aspirate; IS, induced sputum; BAL, bronchoalveolar lavage
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continuation of co-trimoxazole therapy in patients with
negative PCR results and contemplate alternative
diagnoses.
The specificity of PCR for PCP is more difficult to deter-
mine as the organism cannot be cultured and there is no
method to distinguish disease from asymptomatic coloniza-
tion. The large number of IF-negative, PCR-positive sam-
ples may therefore represent children with PCP or with
pneumocystis colonization. As all children were treated for
PCP based on their clinical presentation, it was impossible
to use response to therapy to distinguish active disease
from colonization. The organism has been reported to
colonize the airways of adults with chronic obstructive air-
way disease, with these individuals forming the reservoir
for infection of susceptible hosts [25]. Moreover, positive
PCR results have been reported in BAL samples from
adults without clinical PCP, HIV, or other infections [26].
However, all children in the study had an underlying risk
factor for PCP and were severely ill with a clinical presenta-
tion consistent with PCP. In addition most children were
under 6 months of age, the highest risk period for primary
PCP rather than colonization. It is, therefore, likely that a
positive PCR result in these children represents disease.
To further investigate the specificity of PCR for PCP
samples from 30 control children with confirmed viral
LRT illness who improved clinically without therapy for
PCP, were tested. In contrast to the detection rate in
cases (110, 55%), only a minority (2, 6%) of control chil-
dren were PCR positive. The 2 control positives may
represent primary infection which is very common in
children in the first years of life, and may manifest as a
viral-like illness. Another possible explanation may be
laboratory contamination. However, this is unlikely as
the laboratory layout allows only unidirectional work-
flow with strict separation of all steps in the PCR pro-
cess. The real-time PCR was performed in a closed sys-
tem, with detection occurring on the same platform
thus minimizing the risk of contamination.
An alternative strategy for differentiating colonization
from disease is by applying cut-off values to quantitative
PCR results. Huggett et al were able to achieve a specifi-
city of 96% in BAL specimens from adult patients by
using a quantitative PCR for HSP70, with appropriate
cut-off values [27]. Unfortunately, the quantitative
results obtained in our study could not be accurately
interpreted as data was not normalized by use of a refer-
ence gene as an internal control. Normalization may
control for variations in the extraction process, patient
variability and inter-sample variability by accounting for
the dilution factor in the BAL fluid. However, there is
c o n t r o v e r s ya b o u tt h ec h o i c eo ft h em o s ta p p r o p r i a t e
reference gene [28]. If normalization can be reliably per-
formed, it may allow for more accurate estimation of
colonization rates and of cut-off values to distinguish
disease thus improving the specificity of the assay.
Further work in this area is needed.
Potential difficulties in achieving widespread implemen-
tation of PCR for PCP diagnosis include cost and the need
for a specialized molecular laboratory, equipment, and
personnel. However, much progress has been made in
developing closed molecular amplification platforms for
the diagnosis of TB at point-of-care facilities. Given the
scale of the HIV pandemic and the substantial mortality
associated with PCP particularly in children, a similar
approach for the diagnosis of PCP, should be undertaken.
Conclusion
In summary, this real-time PCR-based assay has a much
higher sensitivity than current diagnostic tests and
allows for the use of a NPA sample for reliable detection
of P. jirovecii in children. PCR on a NPA should replace
the traditional diagnostic method of IF or silver stain
performed on LRT samples. The possibility of making a
reliable diagnosis on a NPA represents an important
advance in confirming PCP in children. Widespread
implementation of this technology is needed especially
in high burden HIV and resource limited settings.
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